Literature DB >> 25182764

Paxillin and steroid signaling: from frog to human.

Stephen R Hammes1, Susanne U Miedlich, Aritro Sen.   

Abstract

Paxillin is a well-characterized cytoplasmic adaptor protein that is known to play important roles in cytoskeletal rearrangement, cell adhesion, and cell motility. In addition to its structural functions, paxillin has more recently been shown to function as a regulator of cell division-mediating steroid-triggered meiosis in oocytes as well as steroid- and growth factor-induced proliferation in prostate and breast cancer. Paxillin mediates these processes through a conserved pathway that involves both extranuclear (nongenomic) and nuclear (genomic) steroid signaling, as well as both cytoplasmic and nuclear kinase signaling. In fact, paxillin appears to serve as a critical liaison between extranuclear and nuclear signaling in response to multiple stimuli, making it a fascinating molecule to study when trying to determine how growth signals from the membrane lead to important proliferative changes in the nucleus. This chapter outlines recent advances in understanding how paxillin regulates both steroid and growth factor signaling, focusing on the conserved nature of its actions from a frog germ cell to a human cancer cell.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25182764      PMCID: PMC5109017          DOI: 10.1007/978-1-4939-1346-6_9

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  57 in total

Review 1.  Paxillin and focal adhesion signalling.

Authors:  C E Turner
Journal:  Nat Cell Biol       Date:  2000-12       Impact factor: 28.824

Review 2.  Minireview: Extranuclear steroid receptors: roles in modulation of cell functions.

Authors:  Ellis R Levin
Journal:  Mol Endocrinol       Date:  2010-09-22

3.  The Mos pathway regulates cytoplasmic polyadenylation in Xenopus oocytes.

Authors:  C H de Moor; J D Richter
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

Review 4.  Comparative aspects of meiotic cell cycle control in mammals.

Authors:  D F Albertini; M J Carabatsos
Journal:  J Mol Med (Berl)       Date:  1998 Nov-Dec       Impact factor: 4.599

Review 5.  The physiology of the Xenopus laevis ovary.

Authors:  Melissa A Rasar; Stephen R Hammes
Journal:  Methods Mol Biol       Date:  2006

Review 6.  Regulation of oocyte maturation.

Authors:  J L Maller; E G Krebs
Journal:  Curr Top Cell Regul       Date:  1980

7.  Sex-steroid hormones and EGF signalling in breast and prostate cancer cells: targeting the association of Src with steroid receptors.

Authors:  Ferdinando Auricchio; Antimo Migliaccio; Gabriella Castoria
Journal:  Steroids       Date:  2008-02-08       Impact factor: 2.668

8.  The Group 3 LIM domain protein paxillin potentiates androgen receptor transactivation in prostate cancer cell lines.

Authors:  Masaaki Kasai; Jennifer Guerrero-Santoro; Robert Friedman; Eddy S Leman; Robert H Getzenberg; Donald B DeFranco
Journal:  Cancer Res       Date:  2003-08-15       Impact factor: 12.701

9.  Phosphorylation-dependent paxillin-ERK association mediates hepatocyte growth factor-stimulated epithelial morphogenesis.

Authors:  Shuta Ishibe; Dominique Joly; Xiaolei Zhu; Lloyd G Cantley
Journal:  Mol Cell       Date:  2003-11       Impact factor: 17.970

10.  Stimulation of Xenopus oocyte maturation by inhibition of the G-protein alpha S subunit, a component of the plasma membrane and yolk platelet membranes.

Authors:  C J Gallo; A R Hand; T L Jones; L A Jaffe
Journal:  J Cell Biol       Date:  1995-07       Impact factor: 10.539

View more
  2 in total

1.  Thapsigargin induces apoptosis of prostate cancer through cofilin-1 and paxillin.

Authors:  Fengyu Huang; Peitao Wang; Xinsheng Wang
Journal:  Oncol Lett       Date:  2018-05-30       Impact factor: 2.967

2.  Expression of Paxillin is Correlated with Clinical Prognosis in Colorectal Cancer Patients.

Authors:  Cheng-jin Zhao; Shuang-kuan Du; Xing-bo Dang; Min Gong
Journal:  Med Sci Monit       Date:  2015-07-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.